Renovaro Inc.
RENB
Get informed when a big investor buys or sells
+ FollowMarket Cap$32.92M
Close$
$-0.37
126.1% downside
Current Fair Value
126.1% downsideOvervalued by 126.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $32.92 Million |
|---|---|
| Enterprise Value | $31.17 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.08 |
| Beta | 0.53 |
| Outstanding Shares | 24,994,200 |
Return
| Return on Equity | 1342.81% |
|---|---|
| Return on Assets | -1300.98% |
| Return on Invested Capital | 1413.20% |
Valuation & Multiples
| P/E Ratio | -0.08 |
|---|---|
| PEG | 0.01 |
| Price to Sales | - |
| Price to Book Ratio | -1.42 |
| Enterprise Value to Revenue | 161.57 |
| Enterprise Value to EBIT | -0.23 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | -0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
February 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.94%▲ 4.18% |
|---|---|
| Total Invested | $981,267▼ 30.60% |
| Investors Holding | 210% |
ESG Score
No data
About Renovaro Biosciences Inc
11 employees
CEO: Eric Leire enochian biosciences (formerly dandrit biotech usa inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for hiv/aids and cancer. the...